Prognostic Value of Serum Total Bilirubin after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome

الملخص EN

Backgrounds.

Previous studies have reported a relationship between serum total bilirubin (STB) and coronary artery disease (CAD).

However, the relationship between STB and prognosis of patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI) remains inconclusive.

The present study aimed to evaluate the relationship between STB level and prognosis of PCI in patients with ACS.

Methods.

In total, 2850 ACS patients who underwent PCI at the Affiliated Zhongda Hospital of Southeast University from June 2009 to Jan 2017 were included in the study.

Twenty-four-hour STB, 30-day, and 1-year postoperative major adverse cardiovascular events (MACE) were recorded.

Subjects were assigned to one of three groups based on STB: Group A (STB ≤ 9.6 μmol/L), Group B (9.7 μmol/L < STB ≤ 15.4 μmol/L), and Group C (STB ≥ 15.5 μmol/L).

COX survival analysis was subsequently used to investigate the relationship between the incidence of MACE and STB in the three groups.

Results.

A total of 2770 subjects were successfully followed up; within 1 year after PCI, 115 (4.15%) subjects died and 191 (6.90%) subjects experienced MACE.

One-year follow-up results showed that the incidence of MACE decreased significantly as STB increased; the risk of Group A was 2.002 times that of Group C (95% CI: 1.342-2.986).

Cardiac mortality also decreased with increasing STB; the risk of Group A was 3.403 times that of Group C (95% CI: 1.319-8.785).

Conclusion.

Lower mortality and MACE incidence rates were found in patients with higher STB within 1 year.

Therefore, STB is highly recommended as an independent long-term prognosis predictor of PCI in patients with ACS.